Methods: The MOST study is an NIH funded cohort study of persons aged 50-79 years with or at risk for knee OA. We measured the ISR on the baseline flexed and weight bearing lateral radiographs in 486 knees, one knee per subject. Cartilage damage, BMLs, and SBA were graded at baseline on MRI using the WORMS scale (0-6, 0-3, and 0-3 respectively) on the patellar and trochlear facets. We divided the ISR into quartiles and dichotomized cartilage damage (≥2), BMLs (≥1), and SBA (≥1) into presence or absence of pathology. We examined the association between the ISR and cartilage damage, BMLs, and SBA in the lateral PFJ using logistic regression with GEE to account for the correlation between patellar and trochlear readings from the same knee. All analyses were adjusted for age, sex, and BMI.
Results: The mean age of the sample was 62, mean BMI 30, mean ISR 1.10, and 60% of subjects were female. Of the 486 knees studied, 35% had cartilage damage, 21% BMLs, and 14% SBA. Compared with subjects in the lowest ISR quartile, those in the highest quartile had 2.7 (95% CI 1.8, 4.4), 3.2 (1.9 5.4), and 6.0 (3.0, 12.4) times more likely to have lateral PFJ cartilage damage, BMLs, and SBA respectively.
Conclusion: Subjects with a high ISR, indicative of patella alta, are more likely to have cartilage damage, BMLs, and SBA in the lateral PFJ, supporting the hypothesis that subjects with an increased ISR have increased PFJ stress. Future research is needed to evaluate whether a high ISR increases the risk of PFJ OA and to investigate the association between the ISR, measures of PFJ alignment, PFJ OA, and pain.
Insall-Salvati Ratio (ISR) | |||||
| Quartile 1 | Quartile2 | Quartile 3 | Quartile 4 | P for trend |
| 0.64-0.99 | 1.00-1.08 | 1.09-1.20 | 1.21-1.58 | (continuous ISR) |
| n=128 knees | n=106 knees | n=128 knees | n=124 knees |
|
| (low) |
|
| (high) |
|
Cartilage Damage |
|
|
|
|
|
% WORMS ≥2 | 25 | 36 | 32 | 46 |
|
Adjusted OR (95% CI)
| 1.0 (reference) | 1.7 (1.0, 2.7) | 1.5 (0.9, 2.3) | 2.7 (1.8, 4.4) | <0.0001
|
Bone Marrow Lesions |
|
|
|
|
|
% WORMS ≥1 | 14 | 19 | 18 | 32 |
|
Adjusted OR (95% CI)
| 1.0 (reference) | 1.4 (0.8, 2.6) | 1.3 (0.7, 2.3) | 3.2 (1.9 5.4) | <0.0001
|
Subchondral Bone Attrition |
|
|
|
|
|
% WORMS ≥1 | 6 | 17 | 10 | 25 |
|
Adjusted OR (95% CI)
| 1.0 (reference) | 3.3 (1.6, 7.0) | 1.7 (0.8, 3.7) | 6.0 (3.0, 12.4) | <0.0001
|
Disclosure: J. J. Stefanik, None; Y. Zhu, None; A. C. Zumwalt, None; K. D. Gross, None; M. Clancy, None; J. A. Lynch, None; L. A. Frey Law, None; C. E. Lewis, None; F. W. Roemer, None; C. M. Powers, None; A. Guermazi, BICL, LLC, 4, Synarc, Inc., 1, GE Healthcare, 2, MerckSerono, Facet Solutions, 5 ; D. T. Felson, None.
![[ Visit Client Website ]](images/banner.gif)